The landscape of genetic medicine in India is shifting from “untreatable” to “engineered solutions.” On September 21st and 22nd, 2024, the Sheraton Grand Bengaluru hosted the Gene Therapy & Precision Medicine Conference (GTPMC2024), a landmark event organized by the Narayana Nethralaya Foundation.

With millions in India affected by rare genetic diseases, the summit served as a critical primer for the next generation of diagnostics and therapeutics. Here are the key highlights from this transformative gathering:

A Visionary Start

The conference was inaugurated by a distinguished roster of leaders, including the Honorable Justice D. Y. Chandrachud, the Chief Justice of India, underscoring the legal and ethical significance of advances in genetics. Human rights activist Smt. Kalpana Das and Mr. Prasanna Kumar Shirol (Co-founder of ORDI) represented the patient community, ensuring that the human element remained at the heart of the scientific discourse.

Core Pillars of Innovation

The summit focused on four primary medical domains where precision medicine is making the most significant impact in India:

• Eye Diseases: Exploring breakthroughs in treating inherited retinal dystrophies.
• Neuromuscular Disorders: Discussing the current management and clinical trial status for inherited muscle diseases.
• Blood Diseases: Advancements in hematology and treatments for rare blood disorders.
• Precision Diagnostics: A focus on improving access to genetic testing and counseling across the country.

Bridging the Gap: Lab to Clinic

GTPMC2024 was structured to move beyond theory and address the practical “Make in India” roadmap for affordable gene therapy. Key sessions included:

• Technology Primers: Determining the right therapy, be it Gene Editing or other nucleic acid-based treatments, for specific diseases
• Indigenous Development: A call for public-private partnerships between institutions like CSIR-IGIB, InStem, and industry leaders like Reliance Life Sciences and Immuneel Therapeutics.
• Regulatory & Ethics: Clear discussions on trial regulations to help patients understand exactly when and how they can enroll in clinical trials.

A Hub for Future Scientists

The conference wasn’t just for experts; it was a training ground. Students, PhDs, and Post-Docs participated in a competitive poster session, showcasing research across all theme-relevant areas. Under the guidance of faculty from prestigious institutions like Johns Hopkins, NCBS, and IIT Bombay, the next generation of Indian scientists gained a firsthand look at the future of ocular and systemic regenerative medicine.

The Takeaway

As summarized by the organizers, the goal of GTPMC2024 was to create a unified network of scientists, physicians, and patient groups. By focusing on Indigenous technology development and affordable gene therapy products, the Narayana Nethralaya Foundation is helping ensure that the “future of sight” and genetic health are accessible to every Indian patient.